Document is current
Any future updates will be listed below
-
Authors
Ray, Aaron
Brett, Alan D.
Dube, Bright
Bowes, Michael A.
Rowbotham, Emma
Conaghan, Philip G.
-
Funding
Funding for this research was provided by:
Centre for Sport, Exercise and Osteoarthritis Research Versus Arthritis, United Kingdom (21595)
Centre for Sport, Exercise and Osteoarthritis Research Versus Arthritis, United Kingdom (21595)
Centre for Sport, Exercise and Osteoarthritis Research Versus Arthritis, United Kingdom (21595)
EPSRC (EP/P001076/1)
EPSRC (EP/P001076/1)
EPSRC (EP/P001076/1)
National Institute for Health and Care Research
British Society of Skeletal Radiologists
Imorphics
Versus Arthritis (20800)
Versus Arthritis (20800)
- License Information
-
More Information
Article History
Received: 5 September 2024
Accepted: 4 March 2025
First Online: 29 April 2025
Declarations
:
: Institutional review boards at all OAI clinical sites and coordinating centre (Memorial Hospital of Rhode Island Institutional Review Board, The Ohio State University’s Biomedical Sciences Institutional Review Board, University of Pittsburgh Institutional Review Board, and University of Maryland Baltimore – Institutional Review Board, and Committee on Human Research at University of California, San Francisco; Approval Number: 10–00532) approved the study. The OAI has been approved and meets all criteria for ethical standards regarding human and animal studies defined in the 1964 Declaration of Helsinki and all amendments made after. All participants provided written informed consent prior to participation.
: Not applicable.
: MAB and ADB are employees of Imorphics, a wholly owned subsidiary of Stryker Corporation. AR, BD and ER have no conflicts of interest to disclose. PGC has done consultancies or speakers bureaus for AbbVie, Bristol Myers Squibb, Eli Lilly, EMD Serono, Flexion Therapeutics, Galapagos, GlaxoSmithKline, Novartis, Pfizer, Roche, Samumed, and Stryker.
